Aeterna Zentaris to Present Proof of Concept for Disorazol Z
Cytotoxic Conjugates such as AEZS-125 in Ovarian Cancer Mouse Model
at Upcoming ENA Symposium
QUÉBEC CITY, Nov. 1, 2012 /CNW
Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that its Director of
Preclinical Development, Babette
Aicher, PhD, will be making a poster presentation on
preclinical results for disorazol Z cytotoxic conjugates, such as
AEZS-125, in ovarian cancer, at the upcoming 24th
EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer
Therapeutics", which will be held November
6-9, 2012 in Dublin,
Ireland. The study is funded through a grant from the German
Ministry of Education and Research.
| Abstract
#330: |
"Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to
a LHRH-Receptor Targeting Peptide, such as AEZS-125, Interfere with
Cell Cycle Progression in Human Cancer Cell Lines and Suppress
Tumor Growth in a LHRH Receptor Positive Ovarian Cancer Xenograft
Model ", B. Aicher, T. Schuster, L. Blumenstein, P. Schmidt, H.
Irschik, R. Jansen, R. Mueller, E. Guenther, M. Teifel. |
| Session: |
Monoclonal Antibodies and Targeted Toxins/Nuclides |
| Poster
Board: |
080 |
| Date& Time:
|
Thursday, November 8, 2012, from 12 noon to 2:15 pm (local
time) |
| Venue: |
Convention Centre Dublin |
About Disorazol Z cytotoxic conjugate, AEZS-125
AEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked
to a Luteinizing Hormone-Releasing Hormone (LHRH)-receptor
targeting peptide. Disorazol Z is a novel natural compound isolated
from myxobacterium Soranglium cellulosum with outstanding
cytotoxic activity. Disorazol Z is a macrocyclic polyketide which
is available via fermentation in high yield and purity. Besides
tubulin binding, disorazol Z has pro-apoptotic properties and
arrested cancer cells in G2 stage of the cell cycle at subnanomolar
concentrations. Disorazol Z is an ideal partner for the formation
of cytotoxic conjugates with peptides and proteins to selectively
target cancer cells.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.